HFS
ARQT icon

Hughes Financial Services’s Arcutis Biotherapeutics ARQT Stock Holding History

Hughes Financial Services’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52 Sell
2
-1
-33% -$23 ﹤0.01% 1586
2026
Q1 		$71 Buy
+3
New +$77 ﹤0.01% 1375

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Hughes Financial Services's ARQT Position: Q2 2026 in Review

Hughes Financial Services reduced its Arcutis Biotherapeutics (ARQT) stake by 33% in Q2 2026, selling an estimated $23 and leaving 2 shares worth $52. The position accounts for ﹤0.01% of the portfolio, ranked #1586.

Hughes Financial Services first reported a position in ARQT in Q1 2026 and has held it in 2 quarters since. The position peaked at $71 in Q1 2026. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Hughes Financial Services held 2 shares of Arcutis Biotherapeutics worth $52 as of Q2 2026.
  • Hughes Financial Services sold 1 Arcutis Biotherapeutics share in Q2 2026, an estimated $23.
  • Arcutis Biotherapeutics made up ﹤0.01% of Hughes Financial Services's portfolio in Q2 2026, its #1586 holding.
  • Hughes Financial Services first reported a position in Arcutis Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • Hughes Financial Services's Arcutis Biotherapeutics position peaked at $71 in Q1 2026.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Hughes Financial Services's 13F filing for Q2 2026, filed 20 Jul 2026.